ESC Congress 2018
ESC 2018: FOURIER analysis: Greater benefit with evolocumab in metabolic syndrome patients
Patients with the metabolic syndrome gained greater clinical benefit from lowering of LDL cholesterol with the PCSK9 inhibitor evolocumab than those without, according to a new analysis from the FOURIER trial presented at the European Society of Cardiology Congress, Munich, Germany (1). Furthermore, clinical benefit…
read more »
ESC 2018: FOURIER: Evolocumab shows similar benefit in men, women and the elderly
Despite the benefit of LDL cholesterol lowering, elderly patients and women are often undertreated. This analysis from the FOURIER trial highlights that the clinical benefit from LDL cholesterol lowering with evolocumab is similar in men and women, and across the age range, including those aged…
read more »
ESC 2018: Real-world data vindicate ESC/EAS guidance for PCSK9 inhibitors
Three presentations at this year’s Congress add support for the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Task Force recommendations for the use of PCSK9 inhibitor treatment in high risk patients in real-world practice (1,2). The first presentation from Professor Ursula Kassner (Charité Berlin,…
read more »
